Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 20, 2008. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under the Deferred Investment Award Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction notifications.
Material Changes
On October 20, 2008, the Administrators of the Deferred Investment Award Plan notified the Company of an increase in share interests for specific individuals following the re-investment of dividends paid on October 9, 2008. The transaction price was £11.08 per share. The specific increases were:
- Mr E J Gray: 260.27 shares
- Mr S A Hussain: 466.51 shares
- Mr D S Redfern: 205.90 shares
- Ms C Thomas: 128.69 shares
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a compliance notification regarding Rule 12g3-2(b) and Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the total number of shares held by the named directors post-transaction.
- Confirm the dividend reinvestment price of £11.08 against market data for October 9, 2008.
- Check subsequent filings for any further changes in director shareholdings.